Please ensure Javascript is enabled for purposes of website accessibility

Why Mallinckrodt Stock Sank Today

By Keith Speights - Updated Nov 26, 2018 at 4:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A negative tweet from a noted short-seller caused the drug stock to tumble.

What happened

Shares of Mallinckrodt (MNK) sank 7.2% as of 3:44 p.m. EST on Monday after dropping as much as 12.8% earlier in the day. The pharmaceutical stock fell on negative tweets from short-seller Citron Research stating that Mallinckrodt had failed in a clinical study of Acthar.

Citron tweeted that the U.S. Department of Health's Office of Inspector General (OIG) and the Medicare Payment Advisory Commission (MEDPAC) "are finally about to put an end to this charade" -- an apparent reference to a controversy about the effectiveness of Acthar. Citron went on to state that Mallinckrodt's "failed clinical studies comes weeks after OIG publishes [sic] that Acthar is a drug based on a history of fraud and abuse." 

Businessman holding thumb down

Image source: Getty Images.

So what

Citron Research and its founder Andrew Left have a mixed history at best in its claims about the impending demise of healthcare stocks. But that doesn't mean Citron and Left don't sometimes make correct calls about a given stock. In the case of Mallinckrodt, the question comes down to whether or not Acthar is truly effective.

The clinical study failure that Citron Research referenced was published on Nov. 15, 2018, in the Clinical Journal of the American Society of Nephrology (CJASN). This study was stopped early "because of a lack of discernible treatment efficacy" for Acthar in treating children with nephrotic syndrome.

One negative clinical study doesn't mean OIG will investigate Mallinckrodt, or that MEDPAC will quit paying for Acthar for Medicare patients. That's especially the case considering that Acthar has been approved for 19 different indications.  

Mallinckrodt Chief Scientific Officer Steven Romano noted in the company's third-quarter conference call that positive data was presented at the American College of Rheumatology conference in October for a phase 4 study of Acthar in treating rheumatoid arthritis. The company is also conducting clinical studies of the drug in treating other indications, including amyotrophic lateral sclerosis (ALS), lupus, multiple sclerosis, and sarcoidosis.

Now what

While Citron Research's tweets likely exaggerated the impact of one clinical study failure, investors should watch closely as Mallinckrodt announces the results for additional clinical studies over the next year. Acthar contributes roughly 45% of the company's total revenue, so any clinical updates will be important.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mallinckrodt Public Limited Company Stock Quote
Mallinckrodt Public Limited Company

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.